ImmunoGen - IMGN Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMGN shares.
View IMGN analyst ratings or view top-rated stocks.

6 brokers have issued twelve-month target prices for ImmunoGen's shares. Their IMGN share price forecasts range from $5.00 to $22.00. On average, they predict the company's stock price to reach $13.13 in the next twelve months. This suggests a possible upside of 149.1% from the stock's current price.
View analysts price targets for IMGN or view top-rated stocks among Wall Street analysts.

ImmunoGen's stock was trading at $7.42 at the beginning of the year. Since then, IMGN stock has decreased by 29.0% and is now trading at $5.27.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our IMGN earnings forecast.

ImmunoGen, Inc. (NASDAQ:IMGN) posted its earnings results on Friday, October, 29th. The biotechnology company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. The biotechnology company had revenue of $9.20 million for the quarter, compared to the consensus estimate of $19.03 million. ImmunoGen had a negative trailing twelve-month return on equity of 75.89% and a negative net margin of 210.33%. The firm's revenue was down 49.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.13) EPS.

ImmunoGen updated its FY 2022 earnings guidance on Friday, November, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $80.00 million-$90.00 million, compared to the consensus revenue estimate of $80.22 million.

16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

ImmunoGen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.90%), Vanguard Group Inc. (7.08%), State Street Corp (6.61%), Jennison Associates LLC (2.81%), Two Sigma Advisers LP (1.36%) and Dimensional Fund Advisors LP (1.15%). Insiders that own company stock include Craig Barrows, David G Foster, Mark J Enyedy and Thomas Ryll.
View institutional ownership trends.

Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IMGN stock can currently be purchased for approximately $5.27.

ImmunoGen (NASDAQ:IMGN) has a market capitalization of $1.16 billion and generates $69.86 million in revenue each year. The biotechnology company earns $-139,300,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

The company employs 106 workers across the globe.

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The official website for the company is www.immunogen.com. The biotechnology company can be reached via phone at (781) 895-0600, via email at courtney.okonek@immunogen.com, or via fax at 781-895-0611.